Previous 10 | Next 10 |
2023-06-11 12:00:02 ET Driven by novel therapeutics from Biogen ( NASDAQ: BIIB )/ Eisai ( OTCPK:ESALF ) and Eli Lilly ( NYSE: LLY ), the Alzheimer’s disease market across eight major countries will reach $13.7B in 2030, the data analytics firm, GlobalData said las...
2023-06-10 18:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-06-10 14:33:38 ET Shares of Biogen Inc ( NASDAQ: BIIB ) gained nearly 10% in extended hours after the biotech firm edged closer to winning FDA approval for its Alzheimer’s drug. FDA panel greenlights Biogen’s Leqembi Late on Friday, advisory committee of t...
FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer's Disease PR Newswire Peripheral and Central Nervous System Drugs Advisory Committee voted based on data from large global confirmator...
2023-06-09 16:22:00 ET An advisory panel of the US Food and Drug Administration has voted unanimously to recommend full approval of Biogen ( NASDAQ: BIIB ) and Eisai's ( OTCPK:ESALF ) ( OTCPK:ESAIY ) Alzheimer's disease drug Leqembi, which would boost the drug's chances of b...
2023-06-09 15:59:23 ET An advisory panel of the US Food and Drug Administration has voted unanimously to recommend full approval of Biogen ( NASDAQ: BIIB ) and Esai's ( OTCPK:ESALF ) ( OTCPK:ESAIY ) Alzheimer's disease drug Leqembi, which would boost the drug's chances of be...
2023-06-07 13:04:36 ET Biogen ( NASDAQ: BIIB ) shares rose Wednesday after the FDA issued what Mizuho described as "super clean" briefing documents on Leqembi, the Alzheimer's therapy developed by the company and its Japanese partner Eisai ( OTCPK:ESALF ) ( OTCPK:ESAIY ), ah...
2023-06-05 10:26:34 ET Denali Therapeutics ( NASDAQ: DNLI ) announced Monday that the company and its partner Biogen ( BIIB ) have decided to discontinue a Phase 3 trial for Parkinson’s disease (PD) candidate BIIB122 (DNL151). The company said the decision follows a r...
2023-06-01 10:33:27 ET In a major boost for developers of Alzheimer's disease treatments, CMS said that it will cover those therapies once granted full, traditional approval. CMS Administrator Chiquita Brooks-LaSure on Thursday said the drugs would be covered "in appropriate settings th...
2023-05-26 06:38:37 ET Elon Musk's brain-implant company Neuralink said in a tweet that it received approval from the U.S. Food and Drug Administration to conduct human clinical trials of the device. "This is the result of incredible work by the Neuralink team in close collaboration wit...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases ...
TOKYO and CAMBRIDGE, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today tha...
NEW YORK, NY / ACCESSWIRE / June 12, 2024 / Leading law firm Bleichmar Fonti & Auld LLP announces the upcoming July 22, 2024, deadline in the Biogen Inc. (Nasdaq:BIIB) Securities Class Action Lawsuit. If you invested in Biogen, you are encouraged to obtain additional information by visiting ...